FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Illana Gozes

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Co-author Network

Publications

TOP 3
Efrat Dresner; Yoav Gothilf; Shahar Alon; Carmit Arviv; Shelly Leibman Barak; Anna Malishkevich; Rivka Ofir; Illana Gozes
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis.
Yan Jouroukhin; Regina Ostritsky; Illana Gozes
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.
Anthony J Harmar; Marc Laburthe; Victor May; Joseph R Pisegna; Jan Fahrenkrug; Illana Gozes; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Illana Gozes (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Efrat Dresner; Yoav Gothilf; Shahar Alon; Carmit Arviv; Shelly Leibman Barak; Anna Malishkevich; Rivka Ofir; Illana Gozes
Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis.
The Journal of biological chemistry 2012;287(48):40173-85.
2012: Yan Jouroukhin; Regina Ostritsky; Illana Gozes
D-NAP prophylactic treatment in the SOD mutant mouse model of amyotrophic lateral sclerosis: review of discovery and treatment of tauopathy.
Journal of molecular neuroscience : MN 2012;48(3):597-602.
2012: Anthony J Harmar; Marc Laburthe; Victor May; Joseph R Pisegna; Jan Fahrenkrug; Illana Gozes; David Vaudry; Hubert Vaudry; James A Waschek; Sami I Said
Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1.
British journal of pharmacology 2012;166(1):4-17.
2012: Illana Gozes
Neuropeptide GPCRs in neuroendocrinology: the case of activity-dependent neuroprotective protein (ADNP).
Frontiers in endocrinology 2012;3():134.
2012: Anat Idan-Feldman; Regina Ostritsky; Illana Gozes
Tau and caspase 3 as targets for neuroprotection.
International journal of Alzheimer's disease 2012;2012():493670.
2012: Michael Gold; Stefan Lorenzl; Bruce H Morimoto; Alistair J Stewart; David R Williams; Illana Gozes
Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.
Neuropsychiatric disease and treatment 2012;8():85-93.
2011: Anat Idan-Feldman; Roza Lagoudaki; Eleni Polyzoidou; Yulie Schirer; Olga Touloumi; Nikolaos Grigoriadis; Illana Gozes
Davunetide (NAP) as a preventative treatment for central nervous system complications in a diabetes rat model.
Neurobiology of disease 2011;44(3):327-39.
2011: Efrat Dresner; Galila Agam; Illana Gozes
Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2011;21(5):355-61.
2011: Mark Belokopytov; Shiri Shulman; Galina Dubinsky; Illana Gozes; Michael Belkin; Mordechai Rosner
Ameliorative effect of NAP on laser-induced retinal damage.
Acta ophthalmologica 2011;89(2):e126-31.
2011: Sheila M Fleming; Caitlin K Mulligan; Franziska Richter; Farzad Mortazavi; Vincent Lemesre; Carmen Frias; Chunni Zhu; Alistair Stewart; Illana Gozes; Bruce Morimoto; Marie-Francoise Chesselet
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions.
Molecular and cellular neurosciences 2011;46(3):597-606.
2011: Illana Gozes
Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Peptides 2011;32(2):428-31.
2011: Illana Gozes
Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Current pharmaceutical design 2011;17(31):3413-7.
2011: Natalia Shiryaev; Regina Pikman; Eliezer Giladi; Illana Gozes
Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Current pharmaceutical design 2011;17(25):2603-12.
2011: Illana Gozes
NAP (davunetide) provides functional and structural neuroprotection.
Current pharmaceutical design 2011;17(10):1040-4.
2010: Illana Gozes
Tau pathology and future therapeutics.
Current Alzheimer research 2010;7(8):685-96.
2010: Illana Gozes
VIP-PACAP 2010: my own perspective on modulation of cognitive and emotional behavior.
Journal of molecular neuroscience : MN 2010;42(3):261-3.
2010: Natalia Shiryaev; Yan Jouroukhin; Illana Gozes
3R tau expression modifies behavior in transgenic mice.
Journal of neuroscience research 2010;88(12):2727-35.
2010: Avia Merenlender-Wagner; Regina Pikman; Eliezer Giladi; Annie Andrieux; Illana Gozes
NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Peptides 2010;31(7):1368-73.
2010: Haim Bassan; Dvora Kidron; Merav Bassan; Michael Rotstein; Naam Kariv; Eliezer Giladi; Ariane Davidson; Illana Gozes; Shaul Harel
The effects of vascular intrauterine growth retardation on cortical astrocytes.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2010;23(7):595-600.
2010: Illana Gozes
Tau pathology: predictive diagnostics, targeted preventive and personalized medicine and application of advanced research in medical practice.
The EPMA journal 2010;1(2):305-16.
2010: Rafael Fernandez-Montesinos; Manuel Torres; David Baglietto-Vargas; Antonia Gutierrez; Illana Gozes; Javier Vitorica; David Pozo Perez
Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.
Journal of molecular neuroscience : MN 2010;41(1):114-20.
2009: Ilona Zemlyak; Nathan Manley; Inna Vulih-Shultzman; Andrew B Cutler; Kevin Graber; Robert M Sapolsky; Illana Gozes
The microtubule interacting drug candidate NAP protects against kainic acid toxicity in a rat model of epilepsy.
Journal of neurochemistry 2009;111(5):1252-63.
2009: Ilona Zemlyak; Robert Sapolsky; Illana Gozes
NAP protects against cyanide-related microtubule destruction.
Journal of neural transmission (Vienna, Austria : 1996) 2009;116(11):1411-6.
2009: Illana Gozes; Alistair Stewart; Bruce Morimoto; Anthony Fox; Karole Sutherland; Donald Schmeche
Addressing Alzheimer's disease tangles: from NAP to AL-108.
Current Alzheimer research 2009;6(5):455-60.
2009: Shmuel Goldberg; Leonid Visochek; Eliezer Giladi; Illana Gozes; Malka Cohen-Armon
PolyADP-ribosylation is required for long-term memory formation in mammals.
Journal of neurochemistry 2009;111(1):72-9.
2009: Ilona Zemlyak; Robert Sapolsky; Illana Gozes
NAP protects against cytochrome c release: inhibition of the initiation of apoptosis.
European journal of pharmacology 2009;618(1-3):9-14.
2009: Hisatsugu Koshimizu; Vladimir Senatorov; Y Peng Loh; Illana Gozes
Neuroprotective protein and carboxypeptidase E.
Journal of molecular neuroscience : MN 2009;39(1-2):1-8.
2009: Natalia Shiryaev; Yan Jouroukhin; Eliezer Giladi; Eleni Polyzoidou; Nikolaos Grigoriadis; Hanna Rosenmann; Illana Gozes
NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model.
Neurobiology of disease 2009;34(2):381-8.
2009: Tal Shprung; Illana Gozes
A novel method for analyzing mitochondrial movement: inhibition by paclitaxel in a pheochromocytoma cell model.
Journal of molecular neuroscience : MN 2009;37(3):254-62.
2008: Adi Malkoff; Abraham Weizman; Illana Gozes; Moshe Rehavi
Decreased M1 muscarinic receptor density in rat amphetamine model of schizophrenia is normalized by clozapine, but not haloperidol.
Journal of neural transmission (Vienna, Austria : 1996) 2008;115(11):1563-71.
2008: Illana Gozes
VIP, from gene to behavior and back: summarizing my 25 years of research.
Journal of molecular neuroscience : MN 2008;36(1-3):115-24.
2008: Seiji Shioda; Hubert Vaudry; Victor May; Karen Braas; Dóra Reglodi; Illana Gozes
In memory of our teacher, Dr. Akira Arimura.
Journal of molecular neuroscience : MN 2008;36(1-3):3-7.
2008: Victor May; Rodney L Parsons; Illana Gozes
8th international symposium on VIP, PACAP related peptides. Introduction.
Journal of molecular neuroscience : MN 2008;36(1-3):1-2.
2008: Shmuel Mandel; Irit Spivak-Pohis; Illana Gozes
ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance.
Journal of molecular neuroscience : MN 2008;35(2):127-41.
2008: Yasuji Matsuoka; Yan Jouroukhin; Audrey J Gray; Li Ma; Chiho Hirata-Fukae; Hui-Fang Li; Li Feng; Laurent Lecanu; Benjamin R Walker; Emmanuel Planel; Ottavio Arancio; Illana Gozes; Paul S Aisen
A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease.
The Journal of pharmacology and experimental therapeutics 2008;325(1):146-53.
2008: Michal Kushnir; Efrat Dresner; Shmuel Mandel; Illana Gozes
Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress.
Journal of neurochemistry 2008;105(2):537-45.
2008: David Dangoor; Barbara Biondi; Marina Gobbo; Yelena Vachutinski; Mati Fridkin; Illana Gozes; Raniero Rocchi
Novel glycosylated VIP analogs: synthesis, biological activity, and metabolic stability.
Journal of peptide science : an official publication of the European Peptide Society 2008;14(3):321-8.
2008: Illana Gozes; Inna Divinski; Inbar Piltzer
NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42).
BMC neuroscience 2008;9 Suppl 3():S3.
2007: Illana Gozes; Inna Divinski
NAP, a neuroprotective drug candidate in clinical trials, stimulates microtubule assembly in the living cell.
Current Alzheimer research 2007;4(5):507-9.
2007: Shmuel Mandel; Illana Gozes
Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex.
The Journal of biological chemistry 2007;282(47):34448-56.
2007: Inna Vulih-Shultzman; Albert Pinhasov; Shmuel Mandel; Nikolaos Grigoriadis; Olga Touloumi; Zipora Pittel; Illana Gozes
Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
The Journal of pharmacology and experimental therapeutics 2007;323(2):438-49.
2007: David Dangoor; Sara Rubinraut; Mati Fridkin; Illana Gozes
Novel analogs of VIP with multiple C-terminal domains.
Peptides 2007;28(9):1622-30.
2007: Alistair J Stewart; Anthony Fox; Bruce H Morimoto; Illana Gozes
Looking for novel ways to treat the hallmarks of Alzheimer's disease.
Expert opinion on investigational drugs 2007;16(8):1183-96.
2007: Illana Gozes
The role of vasoactive intestinal peptide in neuroprotection: Professor Illana Gozes is interviewed by Emma Quigley.
Expert opinion on therapeutic targets 2007;11(6):733-6.
2007: Illana Gozes
Activity-dependent neuroprotective protein: from gene to drug candidate.
Pharmacology & therapeutics 2007;114(2):146-54.
2007: Shmuel Mandel; Gideon Rechavi; Illana Gozes
Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis.
Developmental biology 2007;303(2):814-24.
2007: Eliezer Giladi; Joanna M Hill; Efrat Dresner; Conor M Stack; Illana Gozes
Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo.
Journal of molecular neuroscience : MN 2007;33(3):278-83.
2007: Joanna M Hill; Janet M Hauser; Lia M Sheppard; Daniel Abebe; Irit Spivak-Pohis; Michal Kushnir; Iris Deitch; Illana Gozes
Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry.
Journal of molecular neuroscience : MN 2007;31(3):183-200.
2007: Yasuji Matsuoka; Audrey J Gray; Chiho Hirata-Fukae; S Sakura Minami; Emily Graeme Waterhouse; Mark P Mattson; Frank M LaFerla; Illana Gozes; Paul S Aisen
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage.
Journal of molecular neuroscience : MN 2007;31(2):165-70.
2007: Terry W Moody; Illana Gozes
Vasoactive intestinal peptide receptors: a molecular target in breast and lung cancer.
Current pharmaceutical design 2007;13(11):1099-104.
2007: Jorge Busciglio; Alejandra Pelsman; Pablo Helguera; Osnat Ashur-Fabian; Albert Pinhasov; Douglas E Brenneman; Illana Gozes
NAP and ADNF-9 protect normal and Down's syndrome cortical neurons from oxidative damage and apoptosis.
Current pharmaceutical design 2007;13(11):1091-8.
2006: David Dangoor; Sara Rubinraut; Mati Fridkin; Illana Gozes
Novel extended and branched N-terminal analogs of VIP.
Regulatory peptides 2006;137(1-2):42-9.
2006: Inbar Pilzer; Illana Gozes
VIP provides cellular protection through a specific splice variant of the PACAP receptor: a new neuroprotection target.
Peptides 2006;27(11):2867-76.
2006: Michael Rotstein; Haim Bassan; Naam Kariv; Zipora Speiser; Shaul Harel; Illana Gozes
NAP enhances neurodevelopment of newborn apolipoprotein E-deficient mice subjected to hypoxia.
The Journal of pharmacology and experimental therapeutics 2006;319(1):332-9.
2006: Youssef Sari; Illana Gozes
Brain deficits associated with fetal alcohol exposure may be protected, in part, by peptides derived from activity-dependent neurotrophic factor and activity-dependent neuroprotective protein.
Brain research reviews 2006;52(1):107-18.
2006: Inna Divinski; Miri Holtser-Cochav; Inna Vulih-Schultzman; Ruth A Steingart; Illana Gozes
Peptide neuroprotection through specific interaction with brain tubulin.
Journal of neurochemistry 2006;98(3):973-84.
2006: Francisco J Quintana; Roy Zaltzman; Rafael Fernandez-Montesinos; Juan Luis Herrera; Illana Gozes; Irun R Cohen; David Pozo Perez
NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Annals of the New York Academy of Sciences 2006;1070():500-6.
2006: Inbar Pilzer; Illana Gozes
A splice variant to PACAP receptor that is involved in spermatogenesis is expressed in astrocytes.
Annals of the New York Academy of Sciences 2006;1070():484-90.
2006: Illana Gozes; Irit Spivak-Pohis
Neurotrophic effects of the peptide NAP: a novel neuroprotective drug candidate.
Current Alzheimer research 2006;3(3):197-9.
2006: Ruth A Steingart; Illana Gozes
Recombinant activity-dependent neuroprotective protein protects cells against oxidative stress.
Molecular and cellular endocrinology 2006;252(1-2):148-53.
2006: Miri Holtser-Cochav; Inna Divinski; Illana Gozes
Tubulin is the target binding site for NAP-related peptides: ADNF-9, D-NAP, and D-SAL.
Journal of molecular neuroscience : MN 2006;28(3):303-7.
2005: David Dangoor; Eliezer Giladi; Mati Fridkin; Illana Gozes
Neuropeptide receptor transcripts are expressed in the rat clitoris and oscillate during the estrus cycle in the rat vagina.
Peptides 2005;26(12):2579-84.
2005: Leonid Visochek; Ruth A Steingart; Ina Vulih-Shultzman; Rodica Klein; Esther Priel; Illana Gozes; Malka Cohen-Armon
PolyADP-ribosylation is involved in neurotrophic activity.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2005;25(32):7420-8.
2005: Roy Zaltzman; Alexander Alexandrovich; Victoria Trembovler; Esther Shohami; Illana Gozes
The influence of the peptide NAP on Mac-1-deficient mice following closed head injury.
Peptides 2005;26(8):1520-7.
2005: Illana Gozes; Roy Zaltzman; Janet M Hauser; Douglas E Brenneman; Esther Shohami; Joanna M Hill
The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury.
Current Alzheimer research 2005;2(2):149-53.
2005: Wolf A Lagrèze; Amelie Pielen; Ruth Steingart; Günther Schlunck; Hans-Dieter Hofmann; Illana Gozes; Matthias Kirsch
The peptides ADNF-9 and NAP increase survival and neurite outgrowth of rat retinal ganglion cells in vitro.
Investigative ophthalmology & visual science 2005;46(3):933-8.
2005: Sharon Furman; Joanna M Hill; Inna Vulih; Roy Zaltzman; Janet M Hauser; Douglas E Brenneman; Illana Gozes
Sexual dimorphism of activity-dependent neuroprotective protein in the mouse arcuate nucleus.
Neuroscience letters 2005;373(1):73-8.
2005: Illana Gozes; Bruce H Morimoto; Jacqueline Tiong; Anthony Fox; Karole Sutherland; David Dangoor; Miriam Holser-Cochav; Karin Vered; Paul Newton; Paul S Aisen; Yasuji Matsuoka; Christopher H van Dyck; Leon J Thal
NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP).
CNS drug reviews 2005;11(4):353-68.
2005: Haim Bassan; Merav Bassan; Albert Pinhasov; Naam Kariv; Eliezer Giladi; Illana Gozes; Shaul Harel
The pregnant spontaneously hypertensive rat as a model of asymmetric intrauterine growth retardation and neurodevelopmental delay.
Hypertension in pregnancy : official journal of the International Society for the Study of Hypertension in Pregnancy 2005;24(3):201-11.
2005: Virginia L Smith-Swintosky; Illana Gozes; Douglas E Brenneman; Michael R D'Andrea; Carlos R Plata-Salaman
Activity-dependent neurotrophic factor-9 and NAP promote neurite outgrowth in rat hippocampal and cortical cultures.
Journal of molecular neuroscience : MN 2005;25(3):225-38.
2005: Jolanta B Zawilska; Agnieszka Dejda; Pawel Niewiadomski; Illana Gozes; Jerzy Z Nowak
Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Journal of molecular neuroscience : MN 2005;25(3):215-24.
2004: Margalit Zusev; Illana Gozes
Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP.
Regulatory peptides 2004;123(1-3):33-41.
2004: Illana Gozes; Inna Divinski
The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection.
Journal of Alzheimer's disease : JAD 2004;6(6 Suppl):S37-41.
2004: Illana Gozes; Sharon Furman
Clinical endocrinology and metabolism. Potential clinical applications of vasoactive intestinal peptide: a selected update.
Best practice & research. Clinical endocrinology & metabolism 2004;18(4):623-40.
2004: Sharon Furman; Janet M Hauser; Shmuel Mandel; Ruth A Steingart; Douglas E Brenneman; Illana Gozes
Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes.
Neuron glia biology 2004;1(3):193-9.
2004: Inna Divinski; Leonid Mittelman; Illana Gozes
A femtomolar acting octapeptide interacts with tubulin and protects astrocytes against zinc intoxication.
The Journal of biological chemistry 2004;279(27):28531-8.
2004: Douglas E Brenneman; Catherine Y Spong; Janet M Hauser; Daniel Abebe; Albert Pinhasov; Tania Golian; Illana Gozes
Protective peptides that are orally active and mechanistically nonchiral.
The Journal of pharmacology and experimental therapeutics 2004;309(3):1190-7.
2004: Roy N Alcalay; Eliezer Giladi; Chaim Pick; Illana Gozes
Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze.
Neuroscience letters 2004;361(1-3):128-31.
2004: Illana Gozes
Parkinson's and Alzheimer's diseases: protein aggregations and neuroprotection.
Journal of molecular neuroscience : MN 2004;24(3):333-6.
2004: Roy Zaltzman; Alexander Alexandrovich; Sara M Beni; Victoria Trembovler; Esther Shohami; Illana Gozes
Brain injury-dependent expression of activity-dependent neuroprotective protein.
Journal of molecular neuroscience : MN 2004;24(2):181-7.
2004: Illana Gozes; Ruth A Steingart; Avron D Spier
NAP mechanisms of neuroprotection.
Journal of molecular neuroscience : MN 2004;24(1):67-72.
2004: Illana Gozes
Apolipoprotein E knockout mice as a model of behavioral dysfunction.
Journal of molecular neuroscience : MN 2004;23(3):149-50.
2003: Osnat Ashur-Fabian; Yael Segal-Ruder; Ehud Skutelsky; Douglas E Brenneman; Ruth A Steingart; Eliezer Giladi; Illana Gozes
The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide.
Peptides 2003;24(9):1413-23.
2003: Albert Pinhasov; Shmuel Mandel; Arkady Torchinsky; Eliezer Giladi; Zipora Pittel; Andrew M Goldsweig; Stephen J Servoss; Douglas E Brenneman; Illana Gozes
Activity-dependent neuroprotective protein: a novel gene essential for brain formation.
Brain research. Developmental brain research 2003;144(1):83-90.
2003: Illana Gozes; Douglas E Brenneman
Summer neuropeptide conference. The 3rd joint meeting of the summer neuropeptide conference (13th annual meeting) and the European Neuropeptide Club (13th annual meeting) Montauk, NY, June 8-12, 2003.
Neuropeptides 2003;37(3):157-8.
2003: Jerzy Z Nowak; Paulina Sedkowska; Jolanta B Zawilska; Illana Gozes; Douglas E Brenneman
Antagonism of VIP-stimulated cyclic AMP formation in chick brain.
Journal of molecular neuroscience : MN 2003;20(2):163-72.
2003: Douglas E Brenneman; Terry M Phillips; Janet M Hauser; Joanna M Hill; Catherine Y Spong; Illana Gozes
Complex array of cytokines released by vasoactive intestinal peptide.
Neuropeptides 2003;37(2):111-9.
2003: Roy Zaltzman; Sara M Beni; Eliezer Giladi; Albert Pinhasov; Ruth A Steingart; Jacob Romano; Esther Shohami; Illana Gozes
Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults.
Neuroreport 2003;14(3):481-4.
2003: Illana Gozes; Inna Divinsky; Inbar Pilzer; Mati Fridkin; Douglas E Brenneman; Avron D Spier
From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP: a view of neuroprotection and cell division.
Journal of molecular neuroscience : MN 2003;20(3):315-22.
2003: Illana Gozes
Neuroscience collaborations meeting report: the Israel Society for Neuroscience, and the Institute of Neurosciences, Mental Health and Addiction in Canada, first joint meeting, Sunday, Dec. 15, 2002, Eilat, Israel.
Journal of molecular neuroscience : MN 2003;21(1):55-6.
2003: Illana Gozes; Sharon Furman
VIP and drug design.
Current pharmaceutical design 2003;9(6):483-94.
2002: Illana Gozes
Tau as a drug target in Alzheimer's disease.
Journal of molecular neuroscience : MN 2002;19(3):337-8.
2002: Albert Levy; Rivka Gal; Ruth Granoth; Zeev Dreznik; Mati Fridkin; Illana Gozes
In vitro and in vivo treatment of colon cancer by VIP antagonists.
Regulatory peptides 2002;109(1-3):127-33.
2002: Yoram Wollman; Shmariahu Blumberg; Anya Spungin; Douglas E Brenneman; Mati Fridkin; Jonathan Wollman; Adrian Iaina; Illana Gozes
The increased proliferation of cultured neuroblastoma cells treated with vasoactive intestinal peptide is enhanced by simultaneous inhibition of neutral endopeptidase.
Regulatory peptides 2002;108(2-3):175-7.
2002: Ruth A Steingart; Eitan Heldenberg; Albert Pinhasov; Douglas E Brenneman; Mati Fridkin; Illana Gozes
A vasoactive intestinal peptide receptor analog alters the expression of homeobox genes.
Life sciences 2002;71(21):2543-52.
2002: Sarah H Poggi; Joy Vink; Katie M Goodwin; Joanna M Hill; Douglas E Brenneman; Albert Pinhasov; Illana Gozes; Catherine Y Spong
Differential expression of embryonic and maternal activity-dependent neuroprotective protein during mouse development.
American journal of obstetrics and gynecology 2002;187(4):973-6.
2002: Illana Gozes; Roy Alcalay; Eliezer Giladi; Albert Pinhasov; Sharon Furman; Douglas E Brenneman
NAP accelerates the performance of normal rats in the water maze.
Journal of molecular neuroscience : MN 2002;19(1-2):167-70.
2002: Illana Gozes; Michael D Walker; Alvin M Kaye; Uriel Z Littauer
Protein synthesis in nuclei: when did the story start?
Journal of molecular neuroscience : MN 2002;18(3):167.
2002: Ronen R Leker; Angella Teichner; Nikolaos Grigoriadis; Haim Ovadia; Douglas E Brenneman; Mati Fridkin; Eliezer Giladi; Jacob Romano; Illana Gozes
NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death.
Stroke; a journal of cerebral circulation 2002;33(4):1085-92.
2002: Jacob Romano; Liana Beni-Adani; Orlev Levy Nissenbaum; Douglas E Brenneman; Esther Shohami; Illana Gozes
A single administration of the peptide NAP induces long-term protective changes against the consequences of head injury: gene Atlas array analysis.
Journal of molecular neuroscience : MN 2002;18(1-2):37-45.
2002: Terry W Moody; Robert T Jensen; Mati Fridkin; Illana Gozes
(N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Journal of molecular neuroscience : MN 2002;18(1-2):29-35.
2001: A Sharma; J Walters; Y Gozes; Mati Fridkin; D Brenneman; Illana Gozes; Terry W Moody
A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
Journal of molecular neuroscience : MN 2001;17(3):331-9.
2001: Illana Gozes
Neuroprotective peptide drug delivery and development: potential new therapeutics.
Trends in neurosciences 2001;24(12):700-5.
2001: Illana Gozes; Douglas E Brenneman; P Geppetti; A J Kastin; R E Mains; T W Moody; K Seroogy; Avron D Spier; M Zimmermann
Neuropeptides: brain messengers of many faces.
Trends in neurosciences 2001;24(12):687-90.
2001: E Gelber; Ruth Granoth; Mati Fridkin; Zeev Dreznik; Douglas E Brenneman; Terry W Moody; Illana Gozes
A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
Cancer 2001;92(8):2172-80.
2001: S J Servoss; SJ Lee; G Gibney; Illana Gozes; Douglas E Brenneman; Joanna M Hill
IGF-I as a mediator of VIP/activity-dependent neurotrophic factor-stimulated embryonic growth.
Endocrinology 2001;142(8):3348-53.
2001: Osnat Ashur-Fabian; Eliezer Giladi; Sharon Furman; Ruth A Steingart; Yoram Wollman; Mati Fridkin; Douglas E Brenneman; Illana Gozes
Vasoactive intestinal peptide and related molecules induce nitrite accumulation in the extracellular milieu of rat cerebral cortical cultures.
Neuroscience letters 2001;307(3):167-70.
2001: Terry W Moody; Julius Leyton; D Chan; D C Brenneman; Mati Fridkin; E Gelber; A Levy; Illana Gozes
VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Breast cancer research and treatment 2001;68(1):55-64.
2001: Catherine Y Spong; Daniel Abebe; Illana Gozes; Douglas E Brenneman; Joanna M Hill
Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome.
The Journal of pharmacology and experimental therapeutics 2001;297(2):774-9.
2001: R Zamostiano; Albert Pinhasov; E Gelber; Ruth A Steingart; E Seroussi; Eliezer Giladi; Merav Bassan; Yoram Wollman; H J Eyre; J C Mulley; Douglas E Brenneman; Illana Gozes
Cloning and characterization of the human activity-dependent neuroprotective protein.
The Journal of biological chemistry 2001;276(1):708-14.
2001: Liana Beni-Adani; Illana Gozes; Yoram Cohen; Yaniv Assaf; RA Steingart; Douglas E Brenneman; O Eizenberg; V Trembolver; Esther Shohami
A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.
The Journal of pharmacology and experimental therapeutics 2001;296(1):57-63.
2000: Ilona Zemlyak; Sharon Furman; Douglas E Brenneman; Illana Gozes
A novel peptide prevents death in enriched neuronal cultures.
Regulatory peptides 2000;96(1-2):39-43.
2000: E Sigalov; Mati Fridkin; Douglas E Brenneman; Illana Gozes
VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury.
Journal of molecular neuroscience : MN 2000;15(3):147-54.
2000: Ruth A Steingart; Beka Solomon; Douglas E Brenneman; Mati Fridkin; Illana Gozes
VIP and peptides related to activity-dependent neurotrophic factor protect PC12 cells against oxidative stress.
Journal of molecular neuroscience : MN 2000;15(3):137-45.
2000: Haim Bassan; Leonor Trejo; Naam Kariv; Merav Bassan; E Berger; Aviva Fattal; Illana Gozes; Shaul Harel
Experimental intrauterine growth retardation alters renal development.
Pediatric nephrology (Berlin, Germany) 2000;15(3-4):192-5.
2000: O Blondel; C Collin; W J McCarran; S Zhu; R Zamostiano; Illana Gozes; Douglas E Brenneman; Ronald D G McKay
A glia-derived signal regulating neuronal differentiation.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2000;20(21):8012-20.
2000: Ruth Granoth; Mati Fridkin; Illana Gozes
VIP and the potent analog, stearyl-Nle(17)-VIP, induce proliferation of keratinocytes.
FEBS letters 2000;475(2):78-83.
2000: Ruth Granoth; Mati Fridkin; Sara Rubinraut; Illana Gozes
VIP-derived sequences modified by N-terminal stearyl moiety induce cell death: the human keratinocyte as a model.
FEBS letters 2000;475(2):71-7.
2000: Illana Gozes; Eliezer Giladi; Albert Pinhasov; Amos Bardea; Douglas E Brenneman
Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze.
The Journal of pharmacology and experimental therapeutics 2000;293(3):1091-8.
2000: Illana Gozes; Douglas E Brenneman
A new concept in the pharmacology of neuroprotection.
Journal of molecular neuroscience : MN 2000;14(1-2):61-8.
2000: Daniel Offen; Y Sherki; Eldad Melamed; Mati Fridkin; Douglas E Brenneman; Illana Gozes
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.
Brain research 2000;854(1-2):257-62.
2000: Illana Gozes; R Zamostiano; Albert Pinhasov; Merav Bassan; Eliezer Giladi; Ruth A Steingart; Douglas E Brenneman
A novel VIP responsive gene. Activity dependent neuroprotective protein.
Annals of the New York Academy of Sciences 2000;921():115-8.
2000: Douglas E Brenneman; Catherine Y Spong; Illana Gozes
Protective peptides derived from novel glial proteins.
Biochemical Society transactions 2000;28(4):452-5.
2000: H Zia; Julius Leyton; Marchessini Casibang; V Hau; D Brenneman; Mati Fridkin; Illana Gozes; Terry W Moody
(N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Life sciences 2000;66(5):379-87.
1999: GW Glazner; A Boland; Albert Dresse; Douglas E Brenneman; Illana Gozes; Mark P Mattson
Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death.
Journal of neurochemistry 1999;73(6):2341-7.
1999: Illana Gozes; M Fridkinb; J M Hill; Douglas E Brenneman
Pharmaceutical VIP: prospects and problems.
Current medicinal chemistry 1999;6(11):1019-34.
1999: GW Glazner; P Gressens; SJ Lee; G Gibney; Illana Gozes; Y Gozes; Douglas E Brenneman; Joanna M Hill
Activity-dependent neurotrophic factor: a potent regulator of embryonic growth and development.
Anatomy and embryology 1999;200(1):65-71.
1999: R Zamostiano; Albert Pinhasov; Merav Bassan; O Perl; Ruth A Steingart; R Atlas; Douglas E Brenneman; Illana Gozes
A femtomolar-acting neuroprotective peptide induces increased levels of heat shock protein 60 in rat cortical neurons: a potential neuroprotective mechanism.
Neuroscience letters 1999;264(1-3):9-12.
1999: Illana Gozes; O Perl; Eliezer Giladi; A Davidson; Osnat Ashur-Fabian; Sara Rubinraut; Mati Fridkin
Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(7):4143-8.
1999: Merav Bassan; R Zamostiano; A Davidson; Albert Pinhasov; Eliezer Giladi; O Perl; Haim Bassan; C Blat; G Gibney; GW Glazner; Douglas E Brenneman; Illana Gozes
Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide.
Journal of neurochemistry 1999;72(3):1283-93.
1999: Illana Gozes; Merav Bassan; R Zamostiano; Albert Pinhasov; A Davidson; Eliezer Giladi; O Perl; GW Glazner; Douglas E Brenneman
A novel signaling molecule for neuropeptide action: activity-dependent neuroprotective protein.
Annals of the New York Academy of Sciences 1999;897():125-35.
1999: Joanna M Hill; GW Glazner; SJ Lee; Illana Gozes; P Gressens; Douglas E Brenneman
Vasoactive intestinal peptide regulates embryonic growth through the action of activity-dependent neurotrophic factor.
Annals of the New York Academy of Sciences 1999;897():92-100.
1999: Douglas E Brenneman; Janet M Hauser; Terry M Phillips; A Davidson; Merav Bassan; Illana Gozes
Vasoactive intestinal peptide. Link between electrical activity and glia-mediated neurotrophism.
Annals of the New York Academy of Sciences 1999;897():17-26.
1999: Osnat Ashur-Fabian; O Perl; Gila Lilling; Mati Fridkin; Illana Gozes
SNV, a lipophilic superactive VIP analog, acts through cGMP to promote neuronal survival.
Peptides 1999;20(5):629-33.
1999: Joanna M Hill; SJ Lee; Donald Dibbern; M Fridkin; Illana Gozes; Douglas E Brenneman
Pharmacologically distinct vasoactive intestinal peptide binding sites: CNS localization and role in embryonic growth.
Neuroscience 1999;93(2):783-91.
1998: Terry W Moody; Julius Leyton; Illana Gozes; L Lang; William Eckelman
VIP and breast cancer.
Annals of the New York Academy of Sciences 1998;865():290-6.
1998: Illana Gozes; O Perl; R Zamostiano; Sara Rubinraut; Mati Fridkin; Leah Shochat; Lawrence M Lewin
Multiple actions of a hybrid PACAP antagonist: neuronal cell killing and inhibition of sperm motility.
Annals of the New York Academy of Sciences 1998;865():266-73.
1998: Douglas E Brenneman; GW Glazner; Joanna M Hill; Janet M Hauser; A Davidson; Illana Gozes
VIP neurotrophism in the central nervous system: multiple effectors and identification of a femtomolar-acting neuroprotective peptide.
Annals of the New York Academy of Sciences 1998;865():207-12.
1998: Illana Gozes
In memory of Victor Mutt. Discoveries of biologically important peptides.
Journal of molecular neuroscience : MN 1998;11(2):105-8.
1998: Merav Bassan; R Zamostiano; Eliezer Giladi; A Davidson; Yoram Wollman; J Pitman; Janet M Hauser; Douglas E Brenneman; Illana Gozes
The identification of secreted heat shock 60 -like protein from rat glial cells and a human neuroblastoma cell line.
Neuroscience letters 1998;250(1):37-40.
1998: Douglas E Brenneman; Janet M Hauser; Elaine A Neale; Sara Rubinraut; M Fridkin; A Davidson; Illana Gozes
Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides.
The Journal of pharmacology and experimental therapeutics 1998;285(2):619-27.
1998: Illana Gozes; M Bachar; Amos Bardea; A Davidson; Sara Rubinraut; Mati Fridkin
Protection against developmental deficiencies by a lipophilic VIP analogue.
Neurochemical research 1998;23(5):689-93.
1997: Osnat Ashur-Fabian; Eliezer Giladi; Douglas E Brenneman; Illana Gozes
Identification of VIP/PACAP receptors on rat astrocytes using antisense oligodeoxynucleotides.
Journal of molecular neuroscience : MN 1997;9(3):211-22.
1997: Illana Gozes; M Bachar; Amos Bardea; A Davidson; Sara Rubinraut; Mati Fridkin; Eliezer Giladi
Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: implications for early treatment of Alzheimer's disease.
Journal of neurobiology 1997;33(3):329-42.
1997: Donald Dibbern; GW Glazner; Illana Gozes; Douglas E Brenneman; Joanna M Hill
Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.
The Journal of clinical investigation 1997;99(12):2837-41.
1997: Douglas E Brenneman; Terry M Phillips; B W Festoff; Illana Gozes
Identity of neurotrophic molecules released from astroglia by vasoactive intestinal peptide.
Annals of the New York Academy of Sciences 1997;814():167-73.
1997: Illana Gozes; Amos Bardea; M Bechar; O Pearl; A Reshef; R Zamostiano; A Davidson; Sara Rubinraut; Eliezer Giladi; Mati Fridkin; Douglas E Brenneman
Neuropeptides and neuronal survival: neuroprotective strategy for Alzheimer's disease.
Annals of the New York Academy of Sciences 1997;814():161-6.
1997: Illana Gozes; A Davidson; Y Gozes; R Mascolo; R Barth; D Warren; J Hauser; Douglas E Brenneman
Antiserum to activity-dependent neurotrophic factor produces neuronal cell death in CNS cultures: immunological and biological specificity.
Brain research. Developmental brain research 1997;99(2):167-75.
1997: J Y Wu; K A Henins; P Gressens; Illana Gozes; M Fridkin; Douglas E Brenneman; Joanna M Hill
Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period.
Peptides 1997;18(8):1131-7.
1997: Terry W Moody; Julius Leyton; T Coelho; Sonia B Jakowlew; K Takahashi; F Jameison; M Koh; Mati Fridkin; Illana Gozes; M Knight
(Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.
Life sciences 1997;61(17):1657-66.
1997: Joseph R Pisegna; Julius Leyton; T Coelho; T Hida; Sonia B Jakowlew; Michael J Birrer; Mati Fridkin; Illana Gozes; Terry W Moody
PACAP hybrid: a new PACAP receptor antagonist.
Life sciences 1997;61(6):631-9.
1996: Douglas E Brenneman; Joanna M Hill; Illana Gozes; Terry M Phillips
Vasoactive intestinal peptide releases interleukin-1 from astrocytes.
Annals of the New York Academy of Sciences 1996;805():280-7; discussion 287-9.
1996: Illana Gozes; Gila Lilling; A Davidson; Amos Bardea; A Reshef; R Glazer; R Zamostiano; Osnat Ashur-Fabian; A Ticher; Israel E Ashkenazi; T W Moody; Sara Rubinraut; Mati Fridkin; Douglas E Brenneman
Development of VIP agonists and antagonists with tissue and receptor specificity: effects on behavioral maturation, sexual function, and the biologic clock.
Annals of the New York Academy of Sciences 1996;805():159-69; discussion 169-71.
1996: H Zia; T Hida; Sonia B Jakowlew; Michael J Birrer; Y Gozes; J C Reubi; Mati Fridkin; Illana Gozes; Terry W Moody
Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Cancer research 1996;56(15):3486-9.
1996: Douglas E Brenneman; Illana Gozes
A femtomolar-acting neuroprotective peptide.
The Journal of clinical investigation 1996;97(10):2299-307.
1996: Illana Gozes; Amos Bardea; A Reshef; R Zamostiano; S Zhukovsky; Sara Rubinraut; Mati Fridkin; Douglas E Brenneman
Neuroprotective strategy for Alzheimer disease: intranasal administration of a fatty neuropeptide.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(1):427-32.
1996: Illana Gozes; Douglas E Brenneman
Activity-dependent neurotrophic factor (ADNF). An extracellular neuroprotective chaperonin?
Journal of molecular neuroscience : MN 1996;7(4):235-44.
1996: A Davidson; T W Moody; Illana Gozes
Regulation of VIP gene expression in general. Human lung cancer cells in particular.
Journal of molecular neuroscience : MN 1996;7(2):99-110.
1995: Esther Zoref-Shani; Y Bromberg; Gila Lilling; Illana Gozes; S Brosh; Y Sidi; Oded Sperling
Developmental changes in purine nucleotide metabolism in cultured rat astroglia.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 1995;13(8):887-96.
1995: Illana Gozes; Mati Fridkin; Douglas E Brenneman
A VIP hybrid antagonist: from developmental neurobiology to clinical applications.
Cellular and molecular neurobiology 1995;15(6):675-87.
1995: Douglas E Brenneman; Joanna M Hill; GW Glazner; Illana Gozes; T W Phillips
Interleukin-1 alpha and vasoactive intestinal peptide: enigmatic regulation of neuronal survival.
International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience 1995;13(3-4):187-200.
1995: Illana Gozes; Gila Lilling; R Glazer; A Ticher; Israel E Ashkenazi; A Davidson; Sara Rubinraut; Mati Fridkin; Douglas E Brenneman
Superactive lipophilic peptides discriminate multiple vasoactive intestinal peptide receptors.
The Journal of pharmacology and experimental therapeutics 1995;273(1):161-7.
1994: Illana Gozes; Douglas E Brenneman; Gila Lilling; A Davidson; T W Moody
Neuropeptide regulation of mitosis.
Annals of the New York Academy of Sciences 1994;739():253-61.
1994: Joanna M Hill; R F Mervis; J Politi; Susan K McCune; Illana Gozes; Mati Fridkin; Douglas E Brenneman
Blockade of VIP during neonatal development induces neuronal damage and increases VIP and VIP receptors in brain.
Annals of the New York Academy of Sciences 1994;739():211-25.
1994: Illana Gozes; A Reshef; D Salah; Sara Rubinraut; Mati Fridkin
Stearyl-norleucine-vasoactive intestinal peptide (VIP): a novel VIP analog for noninvasive impotence treatment.
Endocrinology 1994;134(5):2121-5.
1994: R Glazer; Illana Gozes
Diurnal oscillation in vasoactive intestinal peptide gene expression independent of environmental light entraining.
Brain research 1994;644(1):164-7.
1994: Illana Gozes; R Avidor; Eliezer Giladi; Yael Shani; Bruce McEwen; M Dussaillant; W Rostene
Adrenalectomy decreases vasoactive intestinal peptide mRNA levels in the rat suprachiasmatic nucleus.
Neuroscience letters 1994;167(1-2):24-8.
1994: Gila Lilling; Yoram Wollman; M N Goldstein; Sara Rubinraut; Mati Fridkin; Douglas E Brenneman; Illana Gozes
Inhibition of human neuroblastoma growth by a specific VIP antagonist.
Journal of molecular neuroscience : MN 1994;5(4):231-9.
1993: Yoram Wollman; Gila Lilling; M N Goldstein; Mati Fridkin; Illana Gozes
Vasoactive intestinal peptide: a growth promoter in neuroblastoma cells.
Brain research 1993;624(1-2):339-41.
1993: Illana Gozes; Douglas E Brenneman
Neuropeptides as growth and differentiation factors in general and VIP in particular.
Journal of molecular neuroscience : MN 1993;4(1):1-9.
1993: Illana Gozes; J Glowa; Douglas E Brenneman; S K McCune; E Lee; H Westphal
Learning and sexual deficiencies in transgenic mice carrying a chimeric vasoactive intestinal peptide gene.
Journal of molecular neuroscience : MN 1993;4(3):185-93.
1992: Illana Gozes; Mati Fridkin
A fatty neuropeptide. Potential drug for noninvasive impotence treatment in a rat model.
The Journal of clinical investigation 1992;90(3):810-4.
1992: Douglas E Brenneman; M Schultzberg; T Bartfai; Illana Gozes
Cytokine regulation of neuronal survival.
Journal of neurochemistry 1992;58(2):454-60.
1991: Illana Gozes; Susan K McCune; L Jacobson; D Warren; T W Moody; Mati Fridkin; Douglas E Brenneman
An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
The Journal of pharmacology and experimental therapeutics 1991;257(3):959-66.
1990: Eliezer Giladi; Yael Shani; Illana Gozes
The complete structure of the rat VIP gene.
Brain research. Molecular brain research 1990;7(3):261-7.
1990: Douglas E Brenneman; Susan K McCune; Illana Gozes
Acquired immune deficiency syndrome and the developing nervous system.
International review of neurobiology 1990;32():305-53.
1989: R Avidor; Raya Eilam; Rafael Malach; Illana Gozes
VIP-mRNA is increased in hypertensive rats.
Brain research 1989;503(2):304-7.
1989: Illana Gozes; E Meltzer; S Rubinrout; Douglas E Brenneman; Mati Fridkin
Vasoactive intestinal peptide potentiates sexual behavior: inhibition by novel antagonist.
Endocrinology 1989;125(6):2945-9.
1989: R L Holtzman; Rafael Malach; Illana Gozes
Disruption of the optic pathway during development affects vasoactive intestinal peptide mRNA expression.
The New biologist 1989;1(2):215-21.
1989: Illana Gozes; R Avidor; A Biegon; F Baldino
Lactation elevates vasoactive intestinal peptide messenger ribonucleic acid in rat suprachiasmatic nucleus.
Endocrinology 1989;124(1):181-6.
1989: Illana Gozes; Douglas E Brenneman
VIP: molecular biology and neurobiological function.
Molecular neurobiology 1989;3(4):201-36.
1989: Illana Gozes; H Werner; M Fawzi; A Abdelatty; Yael Shani; Mati Fridkin; Yitzhak Koch
Estrogen regulation of vasoactive intestinal peptide mRNA in rat hypothalamus.
Journal of molecular neuroscience : MN 1989;1(1):55-61.
1988: H Werner; Yitzhak Koch; F Baldino; Illana Gozes
Steroid regulation of somatostatin mRNA in the rat hypothalamus.
The Journal of biological chemistry 1988;263(16):7666-71.
1988: Illana Gozes; P Schächter; Yael Shani; Eliezer Giladi
Vasoactive intestinal peptide gene expression from embryos to aging rats.
Neuroendocrinology 1988;47(1):27-31.
1988: Illana Gozes
Biosynthesis and regulation of expression. The vasoactive intestinal peptide gene.
Annals of the New York Academy of Sciences 1988;527():77-87.
1987: Illana Gozes; H Nakai; M Byers; R Avidor; Y Weinstein; Yael Shani; T B Shows
Sequential expression in the nervous system of c-myb and VIP genes, located in human chromosomal region 6q24.
Somatic cell and molecular genetics 1987;13(4):305-13.
1987: Illana Gozes; Eliezer Giladi; Yael Shani
Vasoactive intestinal peptide gene: putative mechanism of information storage at the RNA level.
Journal of neurochemistry 1987;48(4):1136-41.
1987: Illana Gozes; R Avidor; Yaacov Yahav; Daniel Katznelson; C M Croce; K Huebner
The gene encoding vasoactive intestinal peptide is located on human chromosome 6p21----6qter.
Human genetics 1987;75(1):41-4.